Healius updates FY26 guidance with modest earnings growth, flags wage cost pressures from Fair Work ruling, and initiates sale process for high-growth Agilex Biolabs.
- FY26 EBITDA guidance narrowed to $259m-$264m
- Pathology volumes mixed; revenue growth modest
- Fair Work Commission ruling adds $1.8m Q4 cost
- Agilex Biolabs revenue up 13.7%, sale process underway
- Federal Budget offers no new pathology funding
Modest Earnings Growth Amid Mixed Pathology Trends
Healius Limited (ASX:HLS) has revised its FY 2026 earnings outlook, forecasting Group underlying EBITDA between $259 million and $264 million, with EBIT expected in the $30 million to $35 million range. This guidance reflects a cautious stance amid mixed operational signals. Pathology volumes grew 1.2% in the first half but slipped 0.4% over the 10 months to April, while revenue edged up by 3.5% and 2.4% respectively. General practitioner attendances declined slightly, adding to pressure on the core pathology business.
Pathology cost control remains a focus, with labour cost increases contained to 1.1% for the 10 months to April, down from 1.9% at December. Healius anticipates further efficiency gains in the second half of FY 2026, consistent with its ongoing cost rationalisation efforts. These dynamics build on the company’s earlier progress, including a 3.8% revenue rise and digital transformation milestones reported in the first half of the year 3.8% Revenue Growth and Digital Transformation Milestone.
Fair Work Commission Wage Ruling Adds New Cost Pressure
Labour costs in pathology will face a new challenge from the Fair Work Commission’s initial findings on gender-based undervaluation. Healius expects an additional $1.8 million hit in Q4 2026, with phased wage increases for health professionals stretching over five years starting July 2026. The company has already absorbed a 0.8% labour cost rise inclusive of these increases, revising prior guidance that had anticipated flat labour costs for the year.
This ruling compounds existing sector headwinds, as the Federal Government’s recent Budget failed to allocate new funding to pathology services, leaving the sector to absorb rising costs without support. The Budget’s partial restoration of indexation for 2024-25 is offset by tightening Medicare criteria for key tests, intensifying financial strain. Healius warns that these funding gaps are driving closures of collection centres and regional labs, with out-of-pocket fees emerging as the only sustainable response.
Agilex Biolabs Sale Process Initiated to Unlock Value
In a strategic pivot, Healius has engaged UBS Securities Australia Limited to explore the sale of Agilex Biolabs, its standalone specialist diagnostics subsidiary. Agilex has been a bright spot, delivering 13.7% revenue growth year-to-date and bolstering margins through a focus on large molecule development. The move to divest Agilex follows several unsolicited approaches from credible parties and aims to optimise shareholder value without disrupting Healius’ core pathology operations.
The potential sale marks a significant shift from the challenges Agilex faced in prior years, when revenue declines and goodwill impairments weighed on the group. It also aligns with Healius’ broader strategy of streamlining operations and focusing on its pathology franchise, which recently secured a $60 million contract with the Australian Defence Force, leveraging its national network and digital health capabilities $60M Pathology Contract with Australian Defence Force.
Sector Funding Constraints Cast Long Shadow
The pathology sector’s funding environment remains challenging, with the Federal Budget’s freeze on most test indexation compounding cost pressures. Healius highlights the critical role pathology plays in primary healthcare, yet the absence of new funding amid rising wage costs is forcing difficult decisions. The company’s outlook suggests ongoing rationalisation of labour and infrastructure, alongside a growing reliance on patient out-of-pocket fees to bridge the funding shortfall.
Investors will be watching closely for updates on the Agilex sale process and the final Fair Work Commission determination, both of which will materially influence Healius’ cost base and capital allocation strategies in the months ahead.
Bottom Line?
Healius faces a balancing act between cost pressures and asset optimisation as it navigates a tough funding landscape and prepares to potentially divest a key growth asset.
Questions in the middle?
- How will the final Fair Work Commission wage ruling alter Healius’ cost trajectory beyond FY26?
- What valuation and strategic rationale will underpin the Agilex Biolabs sale process?
- Can Healius sustain pathology operations without new government funding amid rising wage costs?